Physician Program
27th Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group
27th Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group | 6th – 9th October 2022 | Kochi, India
27th Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group | 6th – 9th October 2022 | Kochi, India
27th Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group
|
October 06, 2022 (Thrusday) – Day 1 |
||||
|
01.30 PM – 06.00 PM |
Committee meetings and Working Group meetings of APBMT |
|||
|
01:30 PM – 03:30 PM |
APBMT Registry Committee Meeting (Atelier I) |
|||
|
02.30 PM – 03.40 PM |
APBMT Nutrition Support WG’s Meeting (Atelier II) |
|||
|
03:00 PM – 04:00 PM |
APBMT Nuclear Accident Management Meeting (Atelier III) |
|||
|
03.30 PM – 04.30 PM |
Donor Safety Working Group Meeting (Atelier I) |
|||
|
07:00 PM onwards |
Dinner |
|||
|
October 07, 2022 (Friday) – Day 2 |
|||
|
09:00 AM – 09:15 AM |
Opening Remarks Shinichiro Okamoto ( Tokyo), Alok Srivastava (Vellore), Tapan Saikia (Mumbai), Shashikankt Apte (Pune), Navin Khattry (Mumbai) (Hall A & B – Vembanad II & III) Moderator – Revathi Raj (Chennai) |
||
|
09:20 AM – 11:20 AM |
Session 1 Presidential Symposium – Joint Session of ASTCT/EBMT/APBMT/WBMT Chairpersons – Shinichiro Okamoto (Tokyo), Alok Srivastava (Vellore) Moderator – Revathi Raj (Chennai) |
||
|
09:20 AM – 09:50 AM |
Activity and Regulation of Cellular Therapies in North America Miguel Perales, New York |
||
|
09:50 AM – 10:20 AM |
Activity and Regulation of Cellular Therapies in Europe Anna Sureda, Bracelona |
||
|
10:20 AM -10:50 AM |
Activity and Regulation of Cellular Therapies in Asia Pacific Region Shinichiro Okamoto, Tokyo |
||
|
10:50 AM – 11:20 AM |
Global Trends in Cellular Therapy and its integration with HSCT- WBMT Perspective Dietger Niederwieser, Leipzig |
||
|
11:20 AM -12:00 PM |
Plenary Session – Clinical Aspects of TIM-3 in myeloid malignacies- Its relevance in Cellular Therapy Yoshikane Kikushige, Fukuoka Chairpersons: David Ma (Sydney), Tapan Saikia (Mumbai) Moderator – Revathi Raj (Chennai) |
||
|
12:00 PM – 12:15 PM |
Break |
||
|
12:15 PM – 01:15 PM |
Industry Sponsored Lunch Symposium |
||
|
12:15 PM – 01:15 PM |
Gilead/Kite Sponsored Symposium (Hall A – Vembanad III) Moderator: Nishant Jindal (Mumbai) |
Emcure Expert’s Insight in BMT – Indian Evidence (Hall B – Vembanad II) Moderator: Venkateswaran VS (Chennai) |
|
|
12:15 PM – 12:18 PM |
Introduction Francesca Lim, Singapore |
12:15 PM – 12:35 PM |
Chairpersons: Sharat Damodar & Satya Prakash Yadav Optimizing conditioning in adult AML – Indian Evidence on Tro-Flu based Regimen Neeraj Sidharthan |
|
12:18 PM – 12:48 PM |
CAR T-cell therapy in LBCL: From clinical trial to real world evidence Anna Sureda, Barcelona |
12:35 PM – 12:45 PM |
Case Based Panel Discussion on AML Moderator: Neeraj Sidharthan Panel: Satyendra Katewa, Chandran K Nair, Ramaswamy N V, Sameer Tulpule, Reshma Roshan,Jayachandran |
|
12:48 PM – 01:03 PM |
CAR T-celltherapy: A Singapore experience Francesca Lim, Singapore |
12:45 PM – 01:15 PM |
Chairperson: Revathi Raj Panel Discussion: Post BMT viral Infections: Indian Evidence on Cidofovir Moderator: Vikas Dua Panel: Shashikant Apte, Santanu Sen, Kasi Vishwanathan Joseph John, Rajib De |
|
01:03 PM – 01:13 PM |
Q&A Francesca Lim, Singapore Anna Sureda, Barcelona |
||
|
01:13 PM – 01:15 PM |
Closing Francesca Lim, Singapore |
||
|
01:15 PM – 03:15 PM |
Session 2 Acute Leukemia (Hall A – Vembanad III) Chairpersons – Niranjan Rathod (Hamilton) , CN Nair (Thalassery) Moderator: Nishant Jindal (Mumbai) |
Session 3 Pediatric Session (Hall B – Vembanad II) Chairpersons – Ayami Yoshimi (Freiburg), Satya Prakash Yadav (New Delhi) Moderator: Venkateshwaran VS (Chennai) |
|
|
01:15 PM – 01:45 PM |
AML-CR1 Allo-HSCT in the era of genomics Yasuhito Nannya, Kyoto |
Haplo-idential transplant in Thalassemia major current status Usanarat Anurathapan, Nakhon |
|
|
01:45 PM – 02:15 PM |
Prophylactic/Pre-emptive Strategies in AML post allo transplant. What’s relevant in 2022? Auro Viswabandya, Toronto |
HSCT in Primary HLH Amir Hamidieh, Tehran |
|
|
02:15 PM – 02:45 PM |
ALL-CR1 Allo-HSCT in 2022: Who should get it? David Marks, Bristol |
Gene Therapy for Sickle Cell Disease Akshay Sharma, Memphis |
|
|
02:45 PM – 03:15 PM |
Bridge to HSCT for relapsed ALL Peihua Peggy Lu, Beijing |
Upfront Haplo transplant for Aplastic anemias – Are we justified ? Carmen Bonfim, Curitiba |
|
|
03:15 PM- 03:45 PM |
BREAK |
||
|
03:45 PM- 05:45 PM |
Session 4 Lymhoma/Myeloma (Hall A – Vembanad III) Chairpersons – Koji Kato (Fukuoka), Pankaj Malhotra ( Chandigarh) Moderator- Mobin Paul (North Paravoor) |
Session 5 Pediatric Sessions (Hall B – Vembanad II) Chairpersons – Artit Ungkanont (Bangkok) , Sunil Bhat (Bengaluru) Moderator : Ruchira Misra (Mumbai) |
|
|
03:45 PM – 04:15 PM |
Managing Post transplant relapses for Multiple Myeloma Chandramouli Nagarajan, Singapore |
ALL – Optimising conditioning for children Christina Peters , Vienna |
|
|
04:15 PM – 04:45 PM |
Checkpoint Inhibitors or allogeneic transplant in refractory HD Young Rok Do, Daegu |
Cellular Therapy in metastatic neuroblastoma Giuseppe Barone, London |
|
|
04:45 PM – 05:15 PM |
Optimising choices of salvage therapies in DLBCL Ranjit Sahoo, New Delhi |
Late effects post transplant in children and its management Revathi Raj, Chennai |
|
|
05:15 PM – 05:45 PM |
Auto or allo transplant in PTCL Jong Ho Won, Seoul |
Transplantation in Sicle cell Disease- when and how? Selim Corbacioglu, Regensburg |
|
|
05:45 PM – 07:15 PM |
Poster Session – [Exhibition Hall (Physical) + Virtual Platform (Online)] Judges: Shinichiro Okamotoa (Tokyo), Minako Iida (Nagakute), Koichi Miyamura (Inuyama), Reetu Jain (Mumbai), Dharma Chaudhary(New Delhi), Ganesh Jaishetwar (Hyderabad), Neeraj Sidharthan (Kochi), Rajib De (Kolkata), Uday Kulkarni (Vellore), Satyendra Katewa (Jaipur), Santhosh Kumar (Bengaluru), Joseph John (Ludhiana), Punit Jain (Mumbai), Akanksha Chichara (Mumbai) Moderators : Satish Meena (Chennai), Sohini Chakraborty (Chennai), Kaumil Patel(Mumbai), Urmimala Bhatacharjee (Ludhiana) |
||
|
07:15 PM – 08:15 PM |
Industry Sponsored Dinner Symposium – Miltenyi Biotec Sponsored Symposium (Hall A – Vembanad III) Moderator: Dhaarani Jayaraman (Chennai) |
||
|
07:15 PM – 07:18 PM |
Welcome Rene Meissner, Miltenyi Biomedicine |
||
|
07:18 PM – 07:20 PM |
Intro Speaker Rene Meissner, Miltenyi Biomedicine |
||
|
07:20 PM – 07:35 PM |
CART in Pediatric ALL and evolution in Indian Context Sunil Bhat |
||
|
07:35 PM – 07:37 PM |
Intro Speaker Rene Meissner, Miltenyi Biomedicine |
||
|
07:37 PM – 07:52 PM |
Pediatric Haploidentical Hematopoietic Stem Cell transplantation with TCR alpha/beta depletion Pooja Mallya |
||
|
07:52 PM – 07:54 PM |
Intro Speaker Rene Meissner, Miltenyi Biomedicine |
||
|
07:54 PM – 08:09 PM |
Viral-Specific T cells after stem cell transplant Prashant Hiwarkar |
||
|
08:09 PM – 08:15 PM |
Q&A |
||
|
08:15 PM onwards |
Dinner |
||
October 8 ,2022 (Saturday) – Day 3 | ||||
08:00 AM – 09:15 AM | APBMT Business Meeting | |||
(Hall A & B – Vembanad II & III) | ||||
09:15 AM – 09:55 AM | Plenary Session | Cellular therapy Beyond B Cell Malignacies- | ||
09:55 AM – 10:10 AM | Break | |||
10:10 AM- 12:10 PM | Session 6 & 7 | Immunology of Transplantation / GVHD | Infections | |
10:10 AM- 10:40 AM | Non-CNI based GVHD-Prophylaxis strategy: Options and Current Clinical use | Does Gut Microbiome predict infections post transplant | ||
10:40 AM- 11:10 AM | Novel insights in biology and treatment of acute GVHD | Treatment of MDR Gram negative infections- molecular basis of treatment | ||
11:10 AM- 11:40 AM | Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: | PTLD- risk factors, preventive strategies and treatment | ||
11:40 AM- 12:10 PM | Novel insights in biology and treatment of chronic GVHD | Newer insights in treatment of CMV infections | ||
12:10 PM – 12:25 PM | Break | |||
12:25 PM – 01:25 PM | Industry Sponsored Lunch Symposium | |||
Sanofi Sponsored Symposium | Novartis Sponsored Symposium | |||
12:25 PM – 01:10 PM | Haplo-id HSCT and Optimizing patient outcomes with PtCy-ATG combination | 12:25 PM – 12:30 PM | Welcome Address | |
01:10 PM – 01:25 PM | Panel discussion: Moderator: | 12:30 PM – 12:55 PM | Moving beyond Steroids: Ruxolitinib in SR GvHD management | |
12:55 PM – 01:05 PM | Q&A with Prof. Zeiser | |||
01:05 PM – 01:25 PM | Moderator & Case Presenter | |||
01:25 PM-03:25 PM | Session 8 & 9 | Oral Presentations (Abstracts) | Oral Presentations (Abstracts) | |
01:25 PM – 01:35 PM | Fecal Short-Chain Fatty Acids As Biomarker Of Acute Graft Versus Host Disease | Effect Of Stem Cell Dose On Transplant Outcomes In Haplo-SCT | ||
01:35 PM – 01:45 PM | Utility Of Egvhd App For Bedside GVHD Assessment | Prophylactic Versus Preemptive Dli For Patients With High-Risk Acute Leukemia After Allo-HSCT | ||
01:45 PM – 01:55 PM | Withaferin-A Prevents Onset Of Acute Graft Versus Host Disease By Inhibiting JAK2-Stat3 Signaling | The Role Of Allo-Hsct In Acute Leukemia Patients With KMT2A Rearrangement | ||
01:55 PM – 02:05 PM | Withaferin-A Prevents Onset Of Acute Graft Versus Host Disease By Inhibiting JAK2-Stat3 Signaling | A Novel Risk Model For Predicting Early Relapse In Patients With Aml Receiving Allo-HSCT | ||
02:05 PM – 02:15 PM | Outcomes Of Ruxolitinib Use In Steroid Refractory Acute GVHD: A Single Centre Experience From India | IMPROVED SURVIVAL WITH ALLO-HSCT FOR RELAPSED/REFRACTORY B-ALL IN NON-REMISSION OR MRD+ AFTER CART | ||
02:15 PM – 02:25 PM | Micro-Vasculopathy Resulting From Endothelial Damage & GVHD In Recipients Of Allogeneic Transplant | Long Term Outcome Of Hla Matched Allogeneic Transplant In ALL: A Single Centre Experience From India | ||
02:25 PM – 02:35 PM | Genital Graft Versus Host Disease In Children – An Underdiagnosed And Undertreated Entity. | Long Term Outcome Of HLA Matched Allogeneic Transplant In AML: A Single Centre Experience From India | ||
02:35 PM – 02:45 PM | A Prospective Study Of Itolizumab In Indian Patients With Chronic Graft Vs Host Disease-An Update | Outcome Of Hematopoietic Stem Cell Transplantation In Acute Lymphoblastic Leukemia | ||
02:45 PM – 02:55 PM | Efficacy Of Allogenic Cord Blood Platelet Gel On Wounds Of Chronic Skin GVHD Patients After HSCT | The Impact Of Kir Mismatch In Haploidentical Stem Cell Transplantation | ||
02:55 PM – 03:05 PM | Improved Allogenic Transplant Outcomes Following Implementation Of Antimicrobial Stewardship Program | Outcome of TCR Alpha Beta And CD19 Depleted Haploidentical Haematopoietic Stem Cell Transplants | ||
03:05 PM – 03:15 PM | Safety And Efficacy of Granulocyte Transfusions During Hematopoietic Stem Cell Transplant | Pretransplant Immunosuppression Preceding Hematopoietic Stem Cell Transplantation In Thalassemia | ||
03:15 PM – 03:25 PM | Cytomegalovirus Reactivation As A Risk Factor For Mortality In Hematopoietic Stem Cell Transplant | HSCT Offers Superior Survival In Children With Severe Aplastic Anemia In A Tertiary Referral Centre | ||
03:25 PM – 03:45 PM | BREAK | |||
03:45 PM- 04:45 PM | General Assembly Meeting | |||
04:45 PM – 06:45 PM | Session 10 & 11 | Cellular Therapies Beyond Transplantation | Post Transplant complications | |
04:45 PM – 05:15 PM | Cellular Therapy for post transplant infections | Management of non-infective pulmonary complications: What is new? | ||
05:15 PM – 05:45 PM | Indigenous CAR-T product for B Cell Malignancies | Diagnosis and mangement of poor graft function | ||
05:45 PM – 06:15 PM | Gene Corrected HSCT- a reality | Novel conditioning regimens for allogeneic transplantation focusing on AML | ||
06:15 PM – 06:45 PM | Various DLI strategies post transplant to prevent and treat relapse in hematological malignancies | TA-TMA- diagnosis, risk factors and treatment | ||
07:30 PM Onwards | Dinner | |||
|
October 9, 2022 (Sunday) – Day 4 |
||||
|
Hall A |
||||
|
08:50 AM – 09:30 AM |
Plenary Session |
Role of Cell-free DNA profiling in hematopoietic cell transplantation Iwijn De Vlaminck, New York Chairpersons – Anthony Dodds (Sydney), Shashikant Apte (Pune) Moderator: Chepsey Philip |
||
|
09:30 AM – 09:45 AM |
Break |
|||
|
09:45 AM – 11:45 AM |
Session 12 & 13 |
Alternate Donor Transplantation (Hall A – Vembanad III) Chairpersons: William Hwang (Singapore), Dinesh Bhurani (New Delhi) Moderator: Guruprasad CS (Trivandrum) |
Oral Presentations (Abstracts) (Hall B – Vembanad II) Chairpersons : Lynn Bonifacio (Manila), Ajay Sharma (Chandigarh) Moderator: Vikas Dua |
|
|
09:45 AM – 10:15 AM |
How to select donor for T replete and T deplete haplo transplants Piyanuch Kongtim, Irvine |
09:45 AM – 09:55 AM |
Autologous Stem Cell Transplantation In Hodgkin’s Lymphoma- A Single Centre Experience From India Mangai Suseela Murugesan (Abstract ID: 203) |
|
|
10:15 AM – 10:45 AM |
Bone marrow or PBSC- does it really matter in T replete haplo transplants Navneet Majhail, Tennessee |
09:55 AM – 10:05 AM |
Establishing The First Stem Cell Transplant Program In East Africa Sachin Jadhav (Abstract ID: 400) |
|
|
10:45 AM – 11:15 AM |
Haplo vs MUD vs Cord in acute leukemia- current status Ming Yao, Taipei |
10:05 AM – 10:15 AM |
Outcome Of Autologous Stem Cell Transplant For Multiple Myeloma -A Retroprospective Study. Mohmad Hussain Mir (Abstract ID: 386) |
|
|
11:15 AM – 11:45 AM |
Is it the end of the road for cord transplant? Willian Hwang, Singapore |
10:15 AM – 10:25 AM |
Autologous Stem Cell Transplantation For Multiple Myeloma – A Single Center Experience From India Nihar Desai (Abstract ID: 373) |
|
|
10:25 AM – 10:35 AM |
Fertility Outcomes Post Autologous Stem Cell Transplantation For Hodgkin Lymphoma With Lace Regimen Muralidaran C (Abstract ID: 333) |
|||
|
10:35 AM – 10:45 AM |
Comparable Outcomes Of Different Donor Types In Patients With Mds Syndrome Following Allogeneic HSCT Tingting Yang (Abstract ID: 280) |
|||
|
10:45 AM – 10:55 AM |
Allogeneic Hematopoietic Stem Cell Transplantation In Aplastic Anemia – Long Term Outcome Giri Punja (Abstract ID: 363) |
|||
|
10:55 AM – 11:05 AM |
Allogeneic Stem Cell Transplantation For Aplastic Anemia At A Tertiary Care Center In India Satarupa Mahapatra (Abstract ID: 401) |
|||
|
11:05 AM – 11:15 AM |
Bone Marrow Transplantation In Pediatric Inherited Bone Marrow Failure Syndromes: Our Experience Gayathri S (Abstract ID: 162) |
|||
|
11:15 AM – 11:25 AM |
Treosulphan Improves The Outcomes In Allogenic Stem Cell Transplantaion For AML And MDS Patients Chitresh Yadav (Abstract ID: 142) |
|||
|
11:25 AM – 11:35 AM |
Experience With Cytokine-Based Regimens In The Setting Of Autologous Stem Cell Transplantation Sushil Selvarajan (Abstract ID: 409) |
|||
|
11:35 AM – 11:45 AM |
The Outcome Of Hsct In Pediatric Patients With Non-Scid Pid Using Ric Regimens Leila Jafari (Abstract ID: 174) |
|||
|
11:45 AM – 12:00 PM |
Award Announcements and Closing Remarks- Shinichiro Okamoto (Tokyo), Alok Srivastava ( Vellore), Sharat Damodar (Bengaluru) Moderator: Navin Khattry (Hall A) |
|||
|
12:00 PM -01:00 PM |
LUNCH |
|||
Raghu Rajagopal
Executive Advisor, ISBMT
exad@isbmt.org
Ambili Arun Kumar
Chief Operating Officer, ISBMT
coo@isbmt.org
Maheshwari G
Program Manager, ISBMT
pm@isbmt.org
Copyright ©2022 Annual Meeting 2022. All rights reserved.
Powered by WordPress & Designed by Elisyan India Pvt. Ltd.